Table 1.

Effects of different brimonidine eye drops formulations on neutrophil migration

Drugs (1:100 dilution)	Migration distance ± SD (μm)
BT 0.2% with BAK (Alcon Inc)a	62.14 ± 3.71
BT 0.2% with BAK (Allergan Inc)a	63.61 ± 3.81
BT 0.15% without BAK (Allergan Inc)b	40.36 ± 3.17
BAK-Sb	41.02 ± 2.17
PBSc	37.57 ± 2.14
ZASd	77.21 ± 3.95
fMLPd	100.71 ± 3.94

(Mean migration ± standard deviation in μm)

^aDrugs inducing significant chemotaxis (p < 0.01 versus PBS controls)

^bDrugs inducing no significant chemotactic effect (p > 0.05 versus PBS controls)

^cNegative control

^dPositive controls